Doximity (DOCS) Panoramica del titolo
Doximity, Inc. opera come piattaforma digitale per i professionisti del settore medico negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 4/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per DOCS dai nostri controlli di rischio.
DOCS Community Fair Values
Create NarrativeSee what 84 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Doximity, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$24.98 |
| Massimo di 52 settimane | US$76.51 |
| Minimo di 52 settimane | US$20.55 |
| Beta | 1.42 |
| Variazione di 1 mese | 9.71% |
| Variazione a 3 mesi | -33.01% |
| Variazione di 1 anno | -57.90% |
| Variazione a 3 anni | -26.74% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -52.87% |
Notizie e aggiornamenti recenti
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack
Apr 28
DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.
DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.Recent updates
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack
Apr 28DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.
DOCS: AI Tools And Share Buybacks Will Drive Shares Higher
Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook
The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher
Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%
Feb 06
DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement
Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement
Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher
We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.DOCS: Budget Flush And Ad Shift Will Drive Shares Higher
Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Nov 14DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks
Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Sep 02We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve
Aug 15AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely
Jul 08With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case
Jun 23At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
May 17Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
May 01Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value
Apr 04What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You
Feb 23Doximity Q3 Earnings: Outpacing Even Management's Expectations
Feb 10When Should You Buy Doximity, Inc. (NYSE:DOCS)?
Jan 24Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
Jan 13Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching
Jan 06Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
Dec 06Doximity (NYSE:DOCS) Knows How To Allocate Capital
Dec 01Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%
Nov 13Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?
Nov 02Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 15Doximity: Downgrade To Hold On Valuation Concerns
Oct 03Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
Sep 23
Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion
Accelerating adoption of new products and a client portal, alongside strategic positioning with top clients, suggests sustained revenue expansion.There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump
Aug 18Rendimenti per gli azionisti
| DOCS | US Healthcare Services | US Mercato | |
|---|---|---|---|
| 7D | 4.0% | 3.0% | 0.8% |
| 1Y | -57.9% | -37.0% | 27.8% |
Ritorno vs Industria: DOCS ha avuto una performance inferiore rispetto al US Healthcare Services che ha registrato un rendimento -37 % nell'ultimo anno.
Rendimento vs Mercato: DOCS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.8 % nell'ultimo anno.
Volatilità dei prezzi
| DOCS volatility | |
|---|---|
| DOCS Average Weekly Movement | 7.8% |
| Healthcare Services Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: DOCS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di DOCS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2010 | 830 | Jeff Tangney | www.doximity.com |
Doximity, Inc. opera come piattaforma digitale per i professionisti del settore medico negli Stati Uniti. La sua piattaforma fornisce ai suoi membri strumenti digitali costruiti per la medicina, che consentono di collaborare con i colleghi, di tenersi aggiornati sulle ultime notizie e ricerche mediche, di gestire la propria carriera e gli orari di reperibilità, di semplificare la documentazione e le pratiche amministrative e di effettuare visite virtuali ai pazienti. L'azienda serve principalmente medici, infermieri, assistenti, studenti di medicina, produttori farmaceutici e sistemi sanitari.
Doximity, Inc. Riepilogo dei fondamenti
| DOCS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$4.61b |
| Utili (TTM) | US$239.40m |
| Ricavi(TTM) | US$637.78m |
19.3x
Rapporto P/E7.2x
Rapporto P/SDOCS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| DOCS Conto economico (TTM) | |
|---|---|
| Ricavi | US$637.78m |
| Costo del fatturato | US$65.39m |
| Profitto lordo | US$572.39m |
| Altre spese | US$333.00m |
| Utili | US$239.40m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 13, 2026
| Utile per azione (EPS) | 1.30 |
| Margine lordo | 89.75% |
| Margine di profitto netto | 37.54% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato DOCS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 08:45 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Doximity, Inc. è coperta da 32 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Nisala Weerasuriya | Berenberg |